O’Neil Health Care Weekly

XLV rose 10bps last week but reversed from its 50-DMA resistance and broke below its 200-DMA ($132.46) support. Its RS line is
consolidating, warranting an underweight sector positioning. Hospitals lagged due to uncertainties regarding labor costs, pent-up
demand and supply chain. Remain patient, looking for ideas that are trading at logical levels of price or moving average support.

Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq gave back gains from early in the week and closed back below its 50-DMA (4,483/13,881).The market status will shift to an Uptrend Under Pressure should indices close below the follow-through day low (4,432/13,677). The distribution day count stands at four and three respectively.

Utility outperformed all sectors by a wide margin after rising 2.8% this week. Consumer Cyclical, Transportation, and Basic Material rose ~1% while the remaining sectors were relatively flat. Technology lagged significantly and declined 1.6%.

O’Neil Health Care Weekly

XLV declined 113bps last week, breaking back below all key moving averages. There are again multiple levels of resistance including
the 200-DMA ($132.54) followed by the 50-DMA ($133.22). The range of support is between $128.93 to $130.60. Its RS line is
declining, warranting an underweight sector positioning. All industry groups and HC ETFs have near- and intermediate-term
declining relative strength lines, including Med Tech (IHI), Biotech (XBI), Managed Care (IHF), and small cap Health Care (PSCH). PPH
(Pharma) is holding up best due to NVO/LLY. There are few ideas in position to buy. Remain patient and wait for ideas to regain
moving average support.

Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq declined 1.4% and 1.9% for the week. The market
status will shift to an Uptrend Under Pressure should indices close below follow-through day lows (4,432/13,677). The distribution
day count now stands at two and one, respectively. The S&P 500 is trading below its 50-DMA with immediate support at the 100-
DMA 4,347 (-2.3%). The Nasdaq also breached the support level at 50-DMA with next support at its 100-DMA support (13,312;
-3.3%).

O’Neil Health Care Weekly

XLV traded flat for a second straight week, still sitting on 50-DMA ($133.16) support. Immediate resistance is in the $136-$137 range. The sector continues to lag any broader market rally with its RS line again rolling over the past few weeks. We recommend an equal-to- underweight sector positioning. The majority of industry groups and ideas continue to chop sideways with still only a handful of ideas leading within the sector. Remain patient, focusing on ideas rallying from logical support post better-than-expected Q2 results.

O’Neil Health Care Weekly

XLV traded relatively flat last week, holding support at its 200-DMA ($132.54). Immediate resistance is in the $136-$137 range. Its RS
line is still holding trend from July lows, warranting an equal-to-overweight sector positioning. Though XLV has held up better than
the broader market over the last few weeks, relative performance is still tied to only a handful of larger cap Pharmaceuticals. The
majority of ideas are chopping sideways with no trend. Remain patient with a focus on ideas that are holding logical price or moving
average support post better-than-expected earnings.

Market View

The U.S. market status was shifted to a Rally Attempt from a Downtrend on August 23.  The S&P 500 and Nasdaq rose 0.8% and 2.3% for the week. Indices finished with a strong Friday, but still closed in the bottom half of the weekly range. Both were rejected in an attempt to retake and hold above 21/50-DMAs. Primary near-term resistance is again the 21-DMA (S&P 500: 4,440; Nasdaq: 13,667) and then the 50-DMA (S&P 500: 4,460, Nasdaq: 13,811). Still, the attempted rally will remain intact as long as recent lows (S&P 500: 4,335; Nasdaq: 13,161) are not undercut. Friday marked Day six of the rally attempt, with a follow-through day needed to upgrade the status back to a Confirmed Uptrend.

O’Neil Health Care Weekly

XLV declined 158bps last week and is now testing immediate support at its 50-DMA and 200-DMA (~$132.50).
Resistance is around current levels of ~$135.81 followed by $136.85. Its RS line has started to rise, warranting an equalto- overweight sector positioning. Though XLV has held up better than the broader market over the last few weeks,
relative performance is tied to only a handful of larger cap Pharma companies as only three Health Care industry groups
are ranked in the top 40 of 197 O’Neil groups. Remain patient, looking for ideas that are trading at logical levels of price or
moving average support following better-than-expected earnings. There remain few ideas in position to buy.

Market View

The U.S. market status remains in a Downtrend. Indices are trading below their respective 50-DMAs after declining
more than 2% each. The S&P 500 and Nasdaq are testing price support near ~ 4,328 and ~13,334 respectively followed
by their rising 100-DMA (4,297, 10,071).